Indevus Sanctura Comparative Claims Not Supported By NDA, FDA Finds
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Indevus’ NDA for Sanctura did not support a claim that trospium has a superior central nervous system adverse event profile to other anticholinergics, FDA review documents indicate.
You may also be interested in...
Darifenacin, Solifenacin Urinary Incontinence Drugs Could Hit Market In 2003
The urinary incontinence market could see the entry of two significant competitors in 2003, with recent NDA submissions for Pfizer’s darifenacin and Yamanouchi’s solifenacin (YM-905).
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product